D. E. Shaw & Co., Inc. Celldex Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 573,171 shares of CLDX stock, worth $19.1 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
573,171
Previous 23,746
2313.76%
Holding current value
$19.1 Million
Previous $941,000
2456.32%
% of portfolio
0.02%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding CLDX
# of Institutions
207Shares Held
61.2MCall Options Held
291KPut Options Held
246K-
Wellington Management Group LLP Boston, MA7.65MShares$255 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.51MShares$150 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.65MShares$122 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.12MShares$104 Million2.11% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$103 Million0.02% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.56B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...